Physician profile
David E Biddle
NPI 1023218211
$1,441.68
in general payments reported to CMS, 2019-2025
13 companies · $67.63 in 2025
The $67.63 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $345 · 2023: $306 · 2024: $360 · 2025: $67.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $254.35 | 2021-2024 | |
| Depuy Synthes Sales INC. | $238.77 | 2021-2023 | Embotrap, Trufill |
| Janssen Pharmaceuticals, INC | $214.81 | 2021-2022 | |
| Ucb, INC. | $124.99 | 2024 | Nayzilam |
| E.R. Squibb & Sons, L.L.C. | $120.35 | 2022-2025 | Camzyos, Eliquis |
| Alexion Pharmaceuticals, INC. | $114.61 | 2021-2023 | Ultomiris |
| Pfizer INC. | $103.99 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $93.63 | 2021-2024 | Dificid |
| Novo Nordisk INC | $80.66 | 2024 | |
| Novartis Pharmaceuticals Corporation | $47.06 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.34 | 2023 | Jardiance |
| La Jolla Pharmaceutical Company | $14.54 | 2023 | Giapreza |
| Boston Scientific Corporation | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Biddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.